MilliporeSigma and InnoCore Pharmaceuticals of Groningen, Netherlands, have entered into a global cooperation agreement to provide InnoCore’s proprietary SynBiosys biodegradable polymer platform. The drug delivery platform can be used to develop sustained release solutions for biologicals in injectable formulations. “Until now, formulating large biological active pharmaceutical ingredients such as proteins and large peptides into long-acting sustained release formulations has been difficult,…
MilliporeSigma Signs Commercial Supply Agreement With Bluebird Bio
MilliporeSigma today announced that it has signed a commercial supply agreement to manufacture viral vectors for bluebird bio, Inc., of Cambridge, MA, for its use in potentially transformative gene therapies. “We look forward to collaborating with bluebird bio to bring to market breakthrough therapies to fight diseases for which there are limited or no options,” said Udit…
Swiss CDMO Upgrades Manufacturing Facility with Single-Use Bioreactors
MilliporeSigma expands Celonic’s upstream capabilities with Mobius single-use bioreactors. MilliporeSigma announced that Celonic AG, a Swiss contract development and manufacturing organization (CDMO), is upgrading its manufacturing facility with five of MilliporeSigma’s Mobius single-use bioreactors. Celonic, which produces biosimilars and also offers a cell line development platform, will add 50-, 200- and 2,000-liter bioreactors to its development and…
MilliporeSigma Partners with IVI to Develop Scalable Vaccine Manufacturing Processes
MilliporeSigma has entered a research agreement with the International Vaccine Institute (IVI) of Seoul, South Korea to help develop more robust, scalable vaccine manufacturing processes. MilliporeSigma will provide funding and expertise in the areas of clarification and purification. The IVI is a nonprofit international organization committed to the discovery, development and delivery of safe, effective and…
Survey: Managing Risks Associated with the Changing Biopharma Landscape
MilliporeSigma announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks associated with the changing biopharma landscape. The survey, sponsored by MilliporeSigma, was conducted by the Economist Intelligence Unit (EIU), a leading resource for economic and business research, forecasting and analysis. “In response to the uncertainty and disruption facing the…